- Home
- HAE vs OCEAW Comparison
HAE vs OCEAW Comparison
Compare HAE & OCEAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HAE
- OCEAW
- Stock Information
- Founded
- HAE 1971
- OCEAW N/A
- Country
- HAE United States
- OCEAW United States
- Employees
- HAE N/A
- OCEAW 7
- Industry
- HAE Medical/Dental Instruments
- OCEAW Biotechnology: Pharmaceutical Preparations
- Sector
- HAE Health Care
- OCEAW Health Care
- Exchange
- HAE Nasdaq
- OCEAW Nasdaq
- Market Cap
- HAE N/A
- OCEAW N/A
- IPO Year
- HAE 1991
- OCEAW 2021
- Fundamental
- Price
- HAE $63.43
- OCEAW $0.03
- Analyst Decision
- HAE Strong Buy
- OCEAW
- Analyst Count
- HAE 9
- OCEAW 0
- Target Price
- HAE $103.11
- OCEAW N/A
- AVG Volume (30 Days)
- HAE 749.2K
- OCEAW N/A
- Earning Date
- HAE 05-08-2025
- OCEAW N/A
- Dividend Yield
- HAE N/A
- OCEAW N/A
- EPS Growth
- HAE 3.20
- OCEAW N/A
- EPS
- HAE 2.54
- OCEAW N/A
- Revenue
- HAE $1,373,515,000.00
- OCEAW N/A
- Revenue This Year
- HAE $5.04
- OCEAW N/A
- Revenue Next Year
- HAE N/A
- OCEAW N/A
- P/E Ratio
- HAE $24.89
- OCEAW N/A
- Revenue Growth
- HAE 8.13
- OCEAW N/A
- 52 Week Low
- HAE $58.80
- OCEAW N/A
- 52 Week High
- HAE $97.97
- OCEAW N/A
- Technical
- Relative Strength Index (RSI)
- HAE 41.19
- OCEAW N/A
- Support Level
- HAE $63.03
- OCEAW N/A
- Resistance Level
- HAE $64.66
- OCEAW N/A
- Average True Range (ATR)
- HAE 1.74
- OCEAW 0.00
- MACD
- HAE -0.09
- OCEAW 0.00
- Stochastic Oscillator
- HAE 20.94
- OCEAW 0.00
About OCEAW Ocean Biomediacal Inc.
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.